目的观察卡培他滨联合奥沙利铂对晚期大肠癌的疗效。方法采用前瞻性随机对照研究方法,将两院收治的晚期结直肠癌56例随机分为两组,治疗组与对照组各28例,治疗组应用卡培他滨奥沙利铂治疗;对照组应用5-Fu/CF治疗。两周期后评价客观疗效及不良反应。结果治疗组可评价指标21例,有效率(CR/PR)52.3%;对照组可评价指标22例,有效率(CR/1)R)36.4%,P<0.05,差异有显著性。治疗组出现广Ⅰ°以上腹泻6例,Ⅰ°-Ⅱ°恶心、呕吐2例,广骨髓抑制3例,Ⅰ°-Ⅱ°手足综合症3例,对症处理后症状消失。对照组出现Ⅱ°以上胃肠道反应2例,Ⅰ°-Ⅱ°腹泻3例,Ⅰ°骨髓抑制及手足综合症。两组均无1例因药物不良反应而终止治疗及治疗相关性死亡。结论卡培他滨作为新一代5-Fu的口服靶向性药物,联合抗瘤活性较强的奥沙利铂方案,治疗晚期结、直肠癌疗效较好,不良反应轻微,特别是对于5-Fu治疗失效病例仍有疗效,所以卡培他滨联合奥沙利铂是目前治疗结直肠癌的优选方案之一。 Objective To observe the curative effect of capecitabine and oxaliplatin on advanced colorectal cancer. Methods Fifty-six patients with advanced colorectal cancer admitted to our hospital were randomly divided into two groups. The treatment group and control group were treated with oxaliplatin and capecitabine respectively. The control group Application of 5-Fu / CF treatment. Two weeks after the evaluation of objective efficacy and adverse reactions. Results In the treatment group, there were 21 evaluable indicators with effective rate (CR / PR) of 52.3%. In the control group, 22 evaluable indicators (CR / 1) were 36.4%. The difference was significant. In the treatment group, there were 6 cases of diarrhea with a width of 1 ° or above, 2 cases of Ⅰ ° -Ⅱ ° nausea and vomiting, 3 cases of broad myelosuppression and 3 cases of Ⅰ ° -Ⅱ ° hand-foot syndrome. Symptoms disappeared after symptomatic treatment. In the control group, there were 2 cases with gastrointestinal reaction above Ⅱ °, 3 cases with Ⅰ ° -Ⅱ ° diarrhea, Ⅰ ° bone marrow suppression and hand-foot syndrome. None of the two groups discontinued treatment and treatment-related deaths due to adverse drug reactions. Conclusion Capecitabine, as a new generation of 5-Fu oral targeted drugs, combined with strong anti-tumor activity of oxaliplatin regimen in the treatment of advanced node and colorectal cancer has better curative effect and mild side effects, especially for 5- Fu treatment failure cases are still curative, so capecitabine combined with oxaliplatin is currently the treatment of colorectal cancer one of the preferred options.